CS235525B2 - Method of conjugate preparation containing immunoglobulin or immunoglobulin's fragment - Google Patents

Method of conjugate preparation containing immunoglobulin or immunoglobulin's fragment Download PDF

Info

Publication number
CS235525B2
CS235525B2 CS82226A CS22682A CS235525B2 CS 235525 B2 CS235525 B2 CS 235525B2 CS 82226 A CS82226 A CS 82226A CS 22682 A CS22682 A CS 22682A CS 235525 B2 CS235525 B2 CS 235525B2
Authority
CS
Czechoslovakia
Prior art keywords
immunoglobulin
conjugate
fragment
vindesine
solution
Prior art date
Application number
CS82226A
Other languages
Czech (cs)
English (en)
Inventor
George F Rowland
Robin G Simmonds
Original Assignee
Lilly Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Industries Ltd filed Critical Lilly Industries Ltd
Publication of CS235525B2 publication Critical patent/CS235525B2/cs

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6805Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a vinca alkaloid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • External Artificial Organs (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CS82226A 1981-01-12 1982-01-11 Method of conjugate preparation containing immunoglobulin or immunoglobulin's fragment CS235525B2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB8100847 1981-01-12

Publications (1)

Publication Number Publication Date
CS235525B2 true CS235525B2 (en) 1985-05-15

Family

ID=10518931

Family Applications (1)

Application Number Title Priority Date Filing Date
CS82226A CS235525B2 (en) 1981-01-12 1982-01-11 Method of conjugate preparation containing immunoglobulin or immunoglobulin's fragment

Country Status (27)

Country Link
EP (1) EP0056322B1 (ru)
JP (1) JPS57136529A (ru)
KR (1) KR860001149B1 (ru)
AT (1) ATE16603T1 (ru)
AU (1) AU549495B2 (ru)
BG (1) BG40318A3 (ru)
CA (1) CA1180660A (ru)
CS (1) CS235525B2 (ru)
DD (1) DD201447A5 (ru)
DE (1) DE3267474D1 (ru)
DK (1) DK5982A (ru)
EG (1) EG15599A (ru)
ES (1) ES508633A0 (ru)
FI (1) FI820020L (ru)
GB (1) GB2090837B (ru)
GR (1) GR75182B (ru)
HU (1) HU186025B (ru)
IE (1) IE52239B1 (ru)
IL (1) IL64722A (ru)
MX (1) MX7215E (ru)
NZ (1) NZ199421A (ru)
PH (1) PH18031A (ru)
PL (1) PL128529B1 (ru)
PT (1) PT74252B (ru)
RO (1) RO82758B (ru)
SU (1) SU1069628A3 (ru)
ZA (1) ZA82122B (ru)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4639456A (en) * 1980-06-10 1987-01-27 Omnichem S.A. Vinblastin-23-oyl amino acid derivatives
CA1203164A (en) * 1982-03-09 1986-04-15 Thomas J. Mckearn Antibody conjugates
ATE57187T1 (de) * 1983-03-30 1990-10-15 Lilly Industries Ltd Vincaleukoblastin-derivate.
GR79899B (ru) * 1983-03-30 1984-10-31 Lilly Industries Ltd
HUT34212A (en) * 1983-04-29 1985-02-28 Omnichem Sa Process for the production of new vindblastin conjugates
GB2148299B (en) * 1983-09-01 1988-01-06 Hybritech Inc Antibody compositions of therapeutic agents having an extended serum half-life
US4675400A (en) * 1985-06-17 1987-06-23 Eli Lilly And Company Bifunctional derivatives of 4-desacetyl indole-dihydroindole alkaloids
US4667030A (en) * 1985-06-17 1987-05-19 Eli Lilly And Company Hydrazide succinimide derivatives of antineoplastic indole-dihydroindole alkaloids
FI860456A (fi) * 1985-07-16 1987-01-17 Huhtamaeki Oy Laeaeketehdas Le Bis-indolalkaloiders proteinkonjugat, bis-indolalkaloider, deras framstaellning och anvaendning.
EP0232693A3 (fr) * 1985-12-16 1988-04-06 La Region Wallonne Conjugués de la vinblastine et de ses dérivés, procédé pour leur préparation et compositions pharmaceutiques les contenant
US4801688A (en) * 1986-05-27 1989-01-31 Eli Lilly And Company Hydrazone immunoglobulin conjugates
IL82579A0 (en) * 1986-05-27 1987-11-30 Lilly Co Eli Immunoglobulin conjugates
FR2626882B1 (fr) * 1988-02-08 1991-11-08 Ire Celltarg Sa Conjugues de derives de vinca comportant une chaine detergente en position c-3
US5094849A (en) * 1988-08-08 1992-03-10 Eli Lilly And Company Cytotoxic antibody conjugates of hydrazide derivatized vinca analogs via simple organic linkers
US5144012A (en) * 1988-08-08 1992-09-01 Eli Lilly And Company Cytotoxic drug conjugates
US5006652A (en) * 1988-08-08 1991-04-09 Eli Lilly And Company Intermediates for antibody-vinca drug conjugates
US5028697A (en) * 1988-08-08 1991-07-02 Eli Lilly And Company Cytotoxic antibody conjugates of hydrazide derivatized methotrexate analogs via simple organic linkers
US5043340A (en) * 1990-04-03 1991-08-27 Eli Lilly And Company Derivatives of 4-desacetyl VLB C-3 carboxhydrazide

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2456224A1 (de) * 1974-11-28 1976-08-12 Karl Dr Med Theurer Verwendung von nativen antikoerpern oder von antikoerper-fragmenten mit kovalent gebundenen oder konjugierten zytostatisch und/bzw. oder zytotoxisch wirkenden substanzen fuer die krebstherapie
GB1446536A (en) * 1975-02-21 1976-08-18 Yeda Res & Dev Pharmaceutically active compositions
FR2349335A1 (fr) * 1976-04-28 1977-11-25 Inst Int Pathologie Cellulaire Complexes d'alcaloides bis-indoliques du type vinblastine avec la tubuline, leur procede d'obtention et leur utilisation
JPS5470384A (en) * 1977-08-22 1979-06-06 Inst Obu Kiyansaa Risaachi Roi High molecular complex
FR2437213A1 (fr) * 1978-09-28 1980-04-25 Cm Ind Produits cytotoxiques formes par liaison covalente de la chaine a de la ricine avec un anticorps et leur procede de preparation
JPS55136235A (en) * 1979-04-09 1980-10-23 Teijin Ltd Antitumor protein complex and its preparation

Also Published As

Publication number Publication date
EP0056322B1 (en) 1985-11-21
GB2090837B (en) 1984-07-18
IL64722A (en) 1985-07-31
SU1069628A3 (ru) 1984-01-23
IE820023L (en) 1982-07-12
PT74252A (en) 1982-02-01
FI820020L (fi) 1982-07-13
DK5982A (da) 1982-07-13
RO82758B (ro) 1984-01-30
ZA82122B (en) 1983-07-27
IE52239B1 (en) 1987-08-19
CA1180660A (en) 1985-01-08
ES8304149A1 (es) 1983-02-16
PL128529B1 (en) 1984-02-29
IL64722A0 (en) 1982-03-31
GR75182B (ru) 1984-07-13
PL234695A1 (ru) 1982-07-19
DE3267474D1 (en) 1986-01-02
MX7215E (es) 1988-01-08
RO82758A (ro) 1984-01-14
BG40318A3 (en) 1986-11-14
AU7927482A (en) 1982-07-22
ES508633A0 (es) 1983-02-16
NZ199421A (en) 1984-08-24
AU549495B2 (en) 1986-01-30
GB2090837A (en) 1982-07-21
PT74252B (en) 1983-08-24
ATE16603T1 (de) 1985-12-15
KR830008684A (ko) 1983-12-12
HU186025B (en) 1985-05-28
EG15599A (en) 1986-06-30
JPS57136529A (en) 1982-08-23
PH18031A (en) 1985-03-06
EP0056322A1 (en) 1982-07-21
DD201447A5 (de) 1983-07-20
KR860001149B1 (ko) 1986-08-18

Similar Documents

Publication Publication Date Title
CS235525B2 (en) Method of conjugate preparation containing immunoglobulin or immunoglobulin's fragment
US4880935A (en) Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates
US4489710A (en) Composition and method for transplantation therapy
EP0354729B1 (en) Cytotoxic drug conjugates
EP0031999B1 (en) Antitumor protein hybrid and process for the preparation thereof
US5030719A (en) Cytotoxic antibody conjugates and a process for preparation thereof
EP0097518B1 (en) Monoclonal antibody
US4698420A (en) Antibody hybrid molecules and process for their preparation
CA1209472A (en) Anti-cancer drugs for the treatment of leukaemias t constituted by the chain a of ricin and a specific monoclonal antibody
US5006652A (en) Intermediates for antibody-vinca drug conjugates
CZ298024B6 (cs) Zpusoby prípravy monomerních konjugátu nosice a derivátu calicheamicinu
HU189469B (en) Process for preparing antitumour immunoglobulin-derivatives with antibody effect, comprising ricin a subordinate unit
US4263279A (en) Pharmaceutically active compositions containing adriamycin and daunomycin
EP0122132A2 (en) Anti-tumour substance
EP0115171A2 (en) Conjugate having cytotoxicity and process for the preparation thereof
JPS59190924A (ja) 免疫グロブリン接合体
JP2820256B2 (ja) メチルトリチオ抗腫瘍剤のターゲテッド形態
JP3273608B2 (ja) 治療薬の部位特異的インビボ活性化
Sato et al. [6] Derivation and assay of biological effects of monoclonal antibodies to epidermal growth factor receptors
Kulkarni et al. Conjugation of methotrexate to IgG antibodies and their F (ab) 2 fragments and the effect of conjugated methotrexate on tumor growth in vivo
EP0476408A1 (en) Chemical conjugation of morpholino anthracyclines to antibodies
JPS63301832A (ja) イムノグロブリン結合体
NZ212118A (en) Conjugate of macromolecule and ionophore; use as immunotoxin potentiator
Arnon Antibodies and dextran as anti-tumour drug carriers
CA1050012A (en) Conjugates of anti-cancer drugs with antibodies